

Condensed Consolidated Interim Financial Statements

(Expressed in US dollars - unaudited)

Three and nine months ended September 30, 2025 and 2024

Condensed Consolidated Interim Statements of Financial Position As of September 30, 2025 and December 31, 2024 (Expressed in thousands of US dollars - unaudited)

	Note	September 30, 2025	December 31, 2024		
ASSETS					
Current assets					
Cash		\$ 32,062	\$	31,177	
Restricted cash		1,160		518	
Receivables - related parties	10	3,012		1,274	
Other current assets and receivables		1,858		336	
		38,092		33,305	
Non-current assets					
Exploration and evaluation assets	7	26,467		26,446	
Intangible assets		969		943	
Right of use asset		419		482	
Property, plant and equipment		1,099		1,631	
Investment in Aqualung	6	5,350		2,335	
Investment in joint ventures	5	162,514		146,158	
Financial asset - FID	11	51,895		48,138	
Advances and deposits		53		58_	
		248,766		226,191	
TOTAL ASSETS		\$ 286,858	\$	259,496	
LIABILITIES					
Current liabilities					
Accounts payable and accrued liabilities		\$ 3,023	\$	1,104	
Accounts payable - related parties	10	5,878		4,397	
Lease liability - short-term		240		271	
		9,141		5,772	
Non-current liabilities					
Lease liabilities - long-term		179		206	
Deferred income tax liabilities		23,826		24,889	
Decommissioning provision		590		572	
		24,595		25,667	
TOTAL LIABILITIES		33,736		31,439	
TOTAL EINSTEINES		00,700		01,400	
SHAREHOLDERS' EQUITY					
Share capital	9	270,958		235,782	
Reserves	9	37,962		36,040	
Accumulated deficit		(50,502)		(37,849)	
Accumulated other comprehensive loss		(5,296)		(5,916)	
TOTAL SHAREHOLDERS' EQUITY		253,122		228,057	
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		\$ 286,858	\$	259,496	

Approved by the Board of Directors and authorized for issue on November 7, 2025.

"Robert Cross"	"Claudia D'Orazio"
Director	Director

Condensed Consolidated Interim Statements of Comprehensive (Loss) Income For the three and nine months ended September 30, 2025 and 2024 (Expressed in thousands of US dollars, except share and per share amounts - unaudited)

		Three mon Septem	 	Nine mont Septem		
	Note	2025	2024	2025		2024
					rer	Currency neasurement: Note 2
Expenses						
General and administrative		\$ 3,107	\$ 2,811	\$ 7,672	\$	12,910
Demonstration Plant operations	8	1,103	1,039	3,095		4,514
Management and directors' fees	10	508	595	1,490		2,103
Share-based compensation	9	1,802	894	5,088		4,145
Separation benefits		_	748	100		748
Other		6	_	18		_
Foreign exchange (gain) loss		(356)	86	365		(140)
Loss from operations		6,170	6,173	17,828		24,280
Gain on deconsolidation of subsidiaries	4	_	_	_		164,099
Interest and other income		249	75	729		355
Fair value gain on Investment in Aqualung	6	69	_	2,821		_
Fair value gain on financial asset - FID	11	474	1,489	3,757		1,880
Investment loss from Joint Ventures	5	(925)	(423)	(3,169)		(581)
Interest expense		(8)	(15)	(26)		(44)
Net (loss) income before income taxes		(6,311)	(5,047)	(13,716)		141,429
Deferred income tax benefit (expense)		190	218	1,063		(25,652)
Net (loss) income		(6,121)	(4,829)	(12,653)		115,777
Other comprehensive (loss) income						
Item that may be reclassified subsequently to income or loss:						
Currency translation differences of foreign operations		(384)	18	620		16
Total comprehensive (loss) income		\$ (6,505)	\$ (4,811)	\$ (12,033)	\$	115,793
Weighted average number of common shares outstanding						
Basic		204,019,502	184,205,111	197,772,164		182,033,214
Diluted		204,019,502	184,205,111	197,772,164		186,077,372
(Loss) earnings per share		,				
Basic (loss) earnings per share		\$ (0.03)	\$ (0.03)	\$ (0.06)	\$	0.64
Diluted (loss) earnings per share		\$ (0.03)	\$ (0.03)	\$ (0.06)	\$	0.62

Condensed Consolidated Interim Statements of Changes in Equity For the nine months ended September 30, 2025 and 2024 (Expressed in thousands of US dollars, except share amounts - unaudited)

							A	ccumulated other			
	Note	Number of shares	Share capital	Reserves	Α	Accumulated deficit				mprehensive loss	Total equity
December 31, 2023 (Currency remeasurement: Note 2)		174,278,556	\$ 214,270	\$ 31,946	\$	(128,944)	\$	(5,352)	\$ 111,920		
Share-based compensation		_	_	4,145		_		_	4,145		
Shares issued under the ATM	9	9,186,700	12,706	_		_		_	12,706		
Share issuance costs		_	(572)	_		_		_	(572)		
Shares issued in consideration for services		666,667	800	_		_		_	800		
Options exercised		450,000	882	(416)		_		_	466		
Net income		_	_	`—		115,777		_	115,777		
Currency translation differences of foreign operations		_	_	_		_		16	16		
September 30, 2024		184,581,923	\$ 228,086	\$ 35,675	\$	(13,167)	\$	(5,336)	\$ 245,258		
December 31, 2024		188,772,683	\$ 235,782	\$ 36,040	\$	(37,849)	\$	(5,916)	\$ 228,057		
Share-based compensation		_	_	5,088		_		_	5,088		
Shares issued under the ATM	9	16,311,935	32,785	_		_		_	32,785		
Share issuance costs		_	(1,228)	_		_		_	(1,228)		
Conversion of DSUs to common shares		933,740	2,110	(2,110)		_		_			
Vesting of restricted stock units		576,113	649	(649)		_		_	_		
Options exercised		450,000	860	(407)		_		_	453		
Net loss		_	_	`′		(12,653)		_	(12,653)		
Currency translation differences of foreign operations		_	_	_		` _ ′		620	620		
September 30, 2025		207,044,471	\$ 270,958	\$ 37,962	\$	(50,502)	\$	(5,296)	\$ 253,122		

Condensed Consolidated Interim Statements of Cash Flows For the nine months ended September 30, 2025 and 2024 (Expressed in thousands of US dollars - unaudited)

	Note	For the nir ended Sep 2025			
	Note	2020		Currency leasurement : Note 2	
Operating activities					
Net (loss) income	\$	(12,653)	\$	115,777	
Add items not affecting cash					
Share-based compensation	9	5,088		4,145	
Deferred income tax (benefit) expense		(1,063)		25,652	
Foreign exchange loss (gain)	_	409		(196)	
Investment loss from Joint Ventures	5	3,169		581	
Fair value gain on Investment in Aqualung	6	(2,821)			
Fair value gain on financial asset - FID	11	(3,757)		(1,880)	
Gain on deconsolidation of subsidiaries				(164,099)	
Amortization		812		905	
Interest expense		26		44	
Other		18		_	
Net changes in non-cash working capital items:		(0.570)		(4.040)	
Other current assets and receivables		(2,573)		(1,916)	
Advances and deposits		5		(15)	
Accounts payable and accrued liabilities		3,374		4,367	
Net cash used in operating activities		(9,966)		(16,635)	
Investing activities	_				
Joint Venture capital contributions	5	(19,525)			
Exploration and evaluation assets	7	(21)		(8,093)	
Proceeds received from Equinor		_		30,000	
Aqualung Carbon Capture pilot plant development		_		(39)	
Purchase of property, plant and equipment		(222)		(10)	
Change in restricted cash		(639)		(345)	
Patents		(43)			
Net cash (used in) provided by investing activities		(20,228)		21,513	
Financing activities		00.4=0		10 =00	
Proceeds from issuance of shares		32,473		12,706	
Exercise of options				466	
Share issuance costs		(1,197)		(572)	
Lease payments		(252)		(384)	
Net cash provided by financing activities		31,024		12,216	
Effect of exchange rates on cash		55		122	
Net change in cash		885		17,216	
Cash, beginning of period		31,177		11,690	
Cash, end of period	\$	32,062	\$	28,906	
Supplemental cash flow information					
Non-cash investing and financing					
Change in exploration and evaluation expenditures included in accounts payable	\$	_	\$	1,148	
Right of use asset additions	\$	156	\$	_	
Change in share issuance costs included in accounts payable	\$	31	\$		
Change in exercise of options included in accounts receivable	\$	453	\$	_	
Change in proceeds from issuance of shares included in accounts receivable	\$	312	\$	_	

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

1. Nature of Operations

Standard Lithium Ltd. was incorporated under the laws of the Province of British Columbia on August 14, 1998, and was continued under the Canadian Business Corporations Act on December 1, 2016. Standard Lithium Ltd. and its subsidiary entities' (collectively "Standard Lithium" or the "Company") principal operations are comprised of exploration for and development of lithium brine properties in the United States of America. The Company also has significant investments in two joint venture arrangements for the exploration and evaluation of lithium brine projects and the development of production facilities. The address of the Company's corporate office and principal place of business is Suite 1625, 1075 West Georgia Street, Vancouver, British Columbia, Canada, V6E 3C9. The Company's common shares are listed on the TSX Venture Exchange (the "TSXV") and NYSE American, LLC ("NYSE") under the symbol "SLI".

2. Basis of Presentation

Statement of compliance

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standards 34, Interim Financial Reporting ("IAS 34"), as issued by the International Accounting Standards Board ("IASB"). These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements for the six month fiscal period ended December 31, 2024, which have been prepared in accordance with International Financial Reporting Standards as issued by the IASB ("IFRS Accounting Standards").

These condensed consolidated interim financial statements do not include all disclosures required under IFRS Accounting Standards and, accordingly, should be read in conjunction with the consolidated financial statements for the six month fiscal period ended December 31, 2024 and the notes thereto.

These condensed consolidated interim financial statements have been prepared on a going concern basis.

Basis of presentation

These condensed consolidated interim financial statements have been prepared on the historical cost basis except for certain financial instruments and equity investments that are measured at fair value. Financial assets and equity investments classified as fair value through profit or loss ("FVTPL") are measured at their fair value at each reporting date, with changes in fair value recognized in profit or loss during the period in which they arise. Investments in joint ventures over which the Company has significant influence, but not control, are accounted for using the equity method in accordance with IAS 28 Investments in Associates and Joint Ventures. Such investments are initially recognized at cost and are subsequently adjusted to reflect the Company's share of the investee's profits or losses and distributions received.

These condensed consolidated interim financial statements are presented in the United States dollar ("USD"). The functional currency of Standard Lithium is the Canadian dollar ("CAD"). For this entity, all transactions not denominated in CAD functional currency are considered to be foreign currency transactions. Foreign currency denominated monetary assets and liabilities are translated using the rate of exchange prevailing at the reporting date. Gains or losses on translation of these items are included in earnings and reported as foreign exchange loss (gain). Foreign currency denominated non-monetary assets and liabilities, measured at historical cost, are translated at the rate of exchange at the transaction date. The functional currency of all subsidiaries is USD. For these entities, all transactions not denominated in USD functional currency are considered to be foreign currency transactions. Foreign currency denominated monetary assets and liabilities are translated using the rate of exchange prevailing at the reporting date. Gains or losses on translation of these items are included in earnings and reported as foreign exchange loss (gain). Foreign currency denominated non-monetary assets and liabilities, measured at historical cost, are translated at the rate of exchange at the transaction date.

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications have no effect on the reported results of operations.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

Change in fiscal year-end

On November 18, 2024, the Company changed its fiscal year-end from June 30 to December 31. The decision to change the fiscal year-end to a calendar year-end was made to align the Company's reporting cycle more closely with how it manages its business.

Change in presentation currency

Effective July 1, 2024, the Company changed its presentation currency from CAD to USD due to its most significant assets and liabilities being denominated in USD and for consistency with peer companies in the mining industry. This change has been applied retrospectively.

As of June 30, 2024 and all prior periods, the Company's reporting currency was CAD as described in the Company's consolidated financial statements for the six month fiscal period ended December 31, 2024. The currency remeasurement of the Company's results applied the International Accounting Standards ("IAS") transitional rules.

The amounts reported in these condensed consolidated interim financial statements for the periods prior to September 30, 2024 have been remeasured in USD based on the average rate during the respective periods. The accounting policy used to translate equity items prior to September 30, 2024 was to use the historical rate for each equity transaction that occurred to recreate the historical amounts. As of and prior to the three months ended September 30, 2024, equity items were translated quarterly using the average exchange rate for each quarter.

Critical accounting estimates and judgments

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities and contingent liabilities as of the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Estimates and judgments are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

Information about critical judgments in applying accounting policies and assumptions and estimation uncertainties that have the most significant effect on the amounts recognized in the condensed consolidated interim financial statements are disclosed in Note 2 of the Company's consolidated financial statements for the six month fiscal period ended December 31, 2024.

3. Summary of Material Accounting Policies

The significant accounting policies as disclosed in the Company's consolidated financial statements for the six month fiscal period ended December 31, 2024 have been applied consistently in the preparation of these condensed consolidated interim financial statements.

4. Deconsolidation of Subsidiaries

On May 7, 2024, the Company and Equinor TDI Holdings LLC ("Equinor"), a Delaware limited liability company, entered into a membership interest purchase and sale agreement (the "Agreement"), in which Equinor acquired interests in two former Standard Lithium wholly-owned subsidiaries, one of which holds the South West Arkansas Project ("SWA Lithium") and the other holds the East Texas properties ("Texas Lithium") (collectively, the "Joint Ventures"). Pursuant to the terms of the Agreement, Equinor acquired a 45% interest in each of the former subsidiaries, and the Company retained a 55%

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

interest for an initial cash payment of \$30.0 million to the Company and the commitment to invest an additional \$130.0 million as follows:

- Equinor agreed to solely fund the first \$40.0 million and \$20.0 million of development costs for SWA Lithium and Texas Lithium, respectively, after which all additional capital expenditures would be funded on a pro-rata basis; and
- Standard Lithium to receive \$40.0 million in milestone payments associated with SWA Lithium and \$30.0 million in milestone payments associated with Texas Lithium subject to respective final investment decisions being made by certain dates ("FID").

The Company assessed the Agreement and determined its ownership in SWA Lithium and Texas Lithium to be joint ventures. The Agreement gives joint control over each Joint Venture as both parties are required to act together to direct relevant activities and significant decisions regarding SWA Lithium and Texas Lithium require unanimous consent from both parties. However, the Company has retained operatorship and manages day-to-day decision making. The Company deconsolidated SWA Lithium and Texas Lithium and accounted for the Company's investment in SWA Lithium and Texas Lithium under the equity method as the deconsolidated companies are now jointly controlled under a joint venture arrangement. Under this accounting method, the Company's initial recognition of the investment was at fair value. Subsequently, the investment will be adjusted for the Company's share of net income or loss and contributions paid, net of any dividends or distributions received.

The following table summarizes the fair values of the proceeds received and net assets contributed at carrying value to the Joint Ventures, and gain on deconsolidation of subsidiaries recognized for the nine months ended September 30, 2024 (in thousands):

	SWA Lithium	Texas Lithium	Total
Fair value consideration received	\$ 15,000	\$ 15,000	\$ 30,000
Financial asset – FID (1)	27,718	18,977	46,695
Fair value of investment	95,008	52,015	147,023
Less: net assets	(30,116)	(29,503)	(59,619)
Gain on deconsolidation of subsidiaries	\$ 107,610	\$ 56,489	\$ 164,099

⁽¹⁾ The financial asset is comprised of future payments to be received by the Company in connection with the Joint Venture agreements. The receipt of these payments is contingent upon meeting certain milestones. The financial asset is accounted for at fair value. Refer to *Note 11 - Financial Instruments and Financial Risk Management* for further information regarding the fair value.

Standard Lithium's investments in SWA Lithium and Texas Lithium are accounted for using the equity method.

5. Equity Method Investment in Joint Ventures

Changes in the Company's investment in the Joint Ventures for the nine months ended September 30, 2025 are summarized as follows (in thousands):

	SWA			Texas	
		_ithium		Lithium	Total
Balance, December 31, 2024	\$	94,264	\$	51,894	\$ 146,158
Capital contributions		12,375		7,150	19,525
Loss from investment in Joint Ventures		(2,294)		(875)	(3,169)
Balance, September 30, 2025	\$	104,345	\$	58,169	\$ 162,514

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

Summarized financial information for the Company's interest in the Joint Venture entities on a 100% basis for the three months ended September 30, 2025 are (in thousands):

	SWA thium	Texas Lithium	Total
Net loss	\$ 809	\$ 873	\$ 1,682
Company's share of net loss	\$ 445	\$ 480	\$ 925

Summarized financial information for the Company's interest in the Joint Venture entities on a 100% basis for the nine months ended September 30, 2025 are (in thousands):

	SWA ithium	Texas Lithium	Total
Net loss	\$ 4,171	\$ 1,591	\$ 5,762
Company's share of net loss	\$ 2,294	\$ 875	\$ 3,169

Summarized financial information for the Company's interest in the Joint Venture entities on a 100% basis for the three months ended September 30, 2024 are (in thousands):

	SWA ithium	Texas Lithium	Total
Net loss	\$ 628	\$ 142	\$ 770
Company's share of net loss	\$ 345	\$ 78	\$ 423

Summarized financial information for the Company's interest in the Joint Venture entities on a 100% basis for the nine months ended September 30, 2024 are (in thousands):

	SWA :hium	Texas Lithium	Total
Net loss	\$ 791	\$ 269	\$ 1,060
Company's share of net loss	\$ 434	\$ 147	\$ 581

The carrying amount of the Company's investment in the Joint Ventures on a 100% basis as of September 30, 2025 is as follows (in thousands):

	SWA Lithium	Texas Lithium	Total
Current assets ⁽¹⁾	\$ 14,014	\$ 10,332	\$ 24,346
Non-current assets	80,521	55,273	135,794
Total assets	94,535	65,605	160,140
Current liabilities ⁽²⁾	7,430	4,942	12,372
Total liabilities	7,430	4,942	12,372
Net assets	\$ 87,105	\$ 60,663	\$ 147,768
Company's share of joint ventures	47,908	33,365	81,273
Adjustments to the Company's share of net assets ⁽³⁾	56,437	24,804	81,241
Carrying amount of investment in joint ventures	\$ 104,345	\$ 58,169	\$ 162,514

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

- (1) Current assets include \$2.7 million and \$2.0 million due from the Company to SWA Lithium and Texas Lithium, respectively, for reimbursement of costs paid by the Joint Ventures on behalf of the Company.
- (2) Current liabilities include \$1.2 million and \$1.0 million due to the Company from SWA Lithium and Texas Lithium, respectively, for reimbursement of costs paid by the Company on behalf of these entities.
- (3) Adjustments to the Company's share of net assets include the impact of the initial fair value measurement on May 7, 2024 and the impact of Equinor solely funding \$40.0 million and \$20.0 million of capital contributions in SWA Lithium and Texas Lithium, respectively, through September 30, 2025.

6. Investment in Aqualung

As of September 30, 2025, the Company held an equity investment in Aqualung Carbon Capture AS ("Aqualung"), a privately held entity, which is classified as a financial asset measured at fair value through profit or loss in accordance with IFRS 9, Financial Instruments. The fair value of the investment was determined using observable market-based inputs in accordance with IFRS 13, Fair Value Measurement. Aqualung is engaged in the development of carbon capture technology and is based in Norway with operations in the United States. During the nine months ended September 30, 2025, the Company revised its fair value estimate for its investment in Aqualung to \$5.4 million to reflect an equity investment transaction that was completed by Aqualung, which the Company did not participate in. The Company recorded a fair value gain of \$2.8 million during the nine months ended September 30, 2025, primarily as a result of the equity investment transaction.

Changes in the Company's investment in Aqualung for the nine months ended September 30, 2025 are as follows (in thousands):

Balance, December 31, 2024	\$ 2,335
Effect of change in fair value	2,821
Effect of foreign exchange translation	194
Balance, September 30, 2025	\$ 5,350

7. Exploration and Evaluation Assets

	Ev	Commercial Plant Evaluation (Lanxess 1A)			
Acquisition:					
Balance, December 31, 2024	\$	6,000			
Option payments		_			
Balance, September 30, 2025	\$	6,000			
Exploration and Evaluation:					
Balance, December 31, 2024	\$	20,446			
Lanxess 1A evaluation costs		21			
Balance, September 30, 2025	\$	20,467			
Balance, December 31, 2024	\$	26,446			
Balance, September 30, 2025	\$	26,467			

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

8. Demonstration Plant

The Company operates an industrial scale direct lithium extraction ("DLE") demonstration plant (the "Demonstration Plant") in El Dorado, Arkansas. The Demonstration Plant operation costs are comprised of the following (in thousands):

	Three months ended September 30,				Nine months ended September 30,			
	2025	2025 2024			2025		2024	
Personnel	\$ 873	\$	776	\$	2,362	\$	3,054	
Reagents	8		21		48		38	
Repairs and maintenance	28		31		84		49	
Supplies	141		56		442		767	
Test work	3		59		11		401	
Office trailer	19		70		42		114	
Other	31		26		106		91	
Total costs	\$ 1,103	\$	1,039	\$	3,095	\$	4,514	

9. Share Capital

Authorized capital

The Company is authorized to issue an unlimited number of common voting shares without nominal or par value.

During the three and nine months ended September 30, 2025 and 2024, the Company had the following equity transactions:

On November 17, 2023, the Company announced the establishment of an at-the-market ("ATM") equity program allowing the Company to issue and sell up to \$50.0 million of common shares from treasury to the public (the "previous ATM program"). Under the previous ATM program, the Company raised approximately \$50.0 million in total gross proceeds through July of 2025.

On July 23, 2024, the Company signed an agreement with an arms-length third-party advisor to settle a previously accrued fee of \$0.8 million in consideration via the issuance of 666,667 common shares at a deemed price of \$1.20 per common share. The consultant was subsequently appointed as a member of executive management. Services provided prior to joining the executive management team were advisory in nature and did not include management responsibilities.

On August 8, 2025, the Company announced the establishment of an ATM equity program superseding the previous ATM program, which had been fully utilized, allowing the Company to issue and sell up to \$50.0 million of common shares from treasury to the public (the "current ATM program").

As of and during the three and nine months ended September 30, 2025 the Company had issued a total of 1,673,975 common shares under the current ATM program at an average price of \$3.11 for gross and net proceeds of \$5.2 million and \$4.9 million, respectively. This includes 91,500 common shares for which trades were executed on or before September 30, 2025 but settled subsequent to period end, generating gross and net proceeds of \$0.3 million and \$0.3 million, respectively. The related receivable is presented within *Other current assets and receivables* on the Company's condensed consolidated interim statements of financial position.

During the three and nine months ended September 30, 2025, the Company issued a total of 3,475,000 and 14,637,960 common shares, respectively, under the previous ATM program at an average price of \$2.62 and \$1.88, per share, respectively. Gross proceeds provided were \$9.1 million and \$27.6 million, respectively, during the three and nine months ended September 30, 2025 and net proceeds provided were \$8.7 million and \$26.7 million, respectively.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

During the nine months ended September 30, 2024, the Company issued a total of 9,186,700 common shares at an average price of \$1.38 per share, under the previous ATM program. Gross and net proceeds provided were \$12.7 million and \$12.1 million, respectively. There were no common shares issued under the previous ATM program during the three months ended September 30, 2024.

As of September 30, 2025 the Company had issued a total of 28,802,409 common shares under the previous ATM program at an average price of \$1.74 for gross and net proceeds of \$50.0 million and \$47.7 million, respectively.

Options

The Company has a stock option plan in place which authorizes option grants to officers, directors, consultants, management and company employees enabling them to cumulatively acquire up to 10% of the issued and outstanding common stock of the Company pursuant to awards issued under the stock option plan and any other equity compensation arrangements. Under the plan, the exercise price of each option shall not be less than the price permitted by the TSXV. The options can be granted for a maximum term of 10 years and generally have a vesting period of three years.

The weighted average fair value of options granted during the nine months ended September 30, 2025 and 2024 was \$1.18 and \$0.85 per option, respectively. The fair value was determined using the Black-Scholes option-pricing model using the following weighted average assumptions:

	Nine m	e months ended September 30,					
	2	025		2024			
Expected stock price volatility		106%		88%			
Risk-free interest rate		4.00%		2.89%			
Dividend yield		_		_			
Expected life of options		5 years		5 years			
Stock price on date of grant	\$	1.54	\$	1.28			
Forfeiture rate		_		_			

The following table summarizes the option activity for the nine months ended September 30, 2025:

	Number of options	Weighted averag exercise price	_
Balance at December 31, 2024	10,647,246	\$ 2.	2.80
Options granted	2,806,452	1.	.54
Options exercised	(450,000)	1.	.06
Options expired	(525,000)	5.	.83
Balance at September 30, 2025	12,478,698	\$ 2.	.46

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

The following table summarizes options outstanding and exercisable as of September 30, 2025:

			Options Outstanding			Options Exercisable				
Е	xercise Price	Number of Shares	Weighted Average Remaining Contractual Life		Weighted Average xercise Price	Number Exercisable		Veighted Average Exercise Price		
\$	2.66	800,000	0.30	\$	2.66	800,000	\$	2.66		
\$	4.78	200,000	0.80	\$	4.78	200,000	\$	4.78		
\$	4.94	200,000	1.43	\$	4.94	200,000	\$	4.94		
\$	6.52	170,000	1.46	\$	6.52	170,000	\$	6.52		
\$	7.45	100,000	1.53	\$	7.45	100,000	\$	7.45		
\$	3.77	3,225,000	2.53	\$	3.77	3,225,000	\$	3.77		
\$	3.85	200,000	2.65	\$	3.85	200,000	\$	3.85		
\$	2.97	750,000	2.99	\$	2.97	499,999	\$	2.97		
\$	1.07	100,000	3.55	\$	1.07	50,000	\$	1.07		
\$	1.13	1,063,394	3.86	\$	1.13	354,465	\$	1.13		
\$	1.36	2,000,000	3.92	\$	1.36	1,333,334	\$	1.36		
\$	1.42	863,852	4.22	\$	1.42	300,000	\$	1.42		
\$	1.35	1,598,853	4.49	\$	1.35	300,000	\$	1.35		
\$	1.27	557,599	4.50	\$	1.27	<u> </u>	\$	1.27		
\$	1.78	400,000	4.73	\$	1.78	_	\$	1.78		
\$	2.92	250,000	4.88	\$	2.92	_	\$	2.92		
		12,478,698	3.27	\$	2.46	7,732,798	\$	3.03		

Long-term Incentive Plan

The Company has an equity incentive plan ("Plan") in accordance with the policies of the TSXV whereby, from time to time at the discretion of the Board of Directors (the "Board"), eligible directors, officers and employees are awarded restricted share units ("RSUs"). The RSUs that are subject to, among other things, the recipient's deferral right in accordance with the *Income Tax Act* (Canada) convert automatically into common shares upon vesting. In addition, the Company may issue deferred share units ("DSUs"). DSUs may be redeemed upon retirement or termination from the Company. In accordance with the Plan, the aggregate number of common shares to be issued shall not exceed 10% of the Company's issued and outstanding common shares at any given time when combined with the aggregate number of options, RSUs and DSUs issued pursuant to the Plan and any other equity compensation arrangements.

The following table summarizes the RSU activity for the nine months ended September 30, 2025:

	Number of RSUs	Weighted average grant date fair value
Balance at December 31, 2024	1,780,614	\$ 1.18
Granted	1,463,192	1.33
Vested	(576,113)	1.13
Forfeited	(35,354)	1.13
Balance at September 30, 2025	2,632,339	\$ 1.28

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

The following table summarizes the DSU activity for the nine months ended September 30, 2025:

	Number of DSUs	Weighted average grant date fair value				
Balance at December 31, 2024	2,425,609	\$ 3.09				
Granted	501,856	1.35				
Conversion of DSUs to common shares	(933,740)	3.77				
Balance at September 30, 2025	1,993,725	\$ 2.36				

Share-based compensation expense

Share-based compensation recorded for each type of award is as follows (in thousands):

	Three months ended September 30,				Nine mon Septen		
	2025		2024		2025		2024
Options	\$ 964	\$	673	\$	2,720	\$	1,830
RSUs	550		149		1,537		149
DSUs	288		72		831		2,166
Total	\$ 1,802	\$	894	\$	5,088	\$	4,145

10. Related Party Transactions

Key management personnel are persons responsible for planning, directing and controlling the activities of the entity, which are the directors and officers of the Company.

Compensation to key management is comprised of the following (in thousands):

		Three months ended September 30,				Nine months ended September 30,			
	2025 2024		2025			2024			
Management and director fees ⁽¹⁾	\$	508	\$	595	\$	1,490	\$	2,103	
Separation benefits ⁽²⁾		_		748		_		748	
Share-based compensation		1,010		687		3,573		2,704	
	\$	1,518	\$	2,030	\$	5,063	\$	5,555	

- (1) Management and director fees are comprised of salaries, bonuses, benefits and directors' fees included on the Company's interim condensed consolidated statement of comprehensive loss.
- (2) Separation benefits include severance payments to former officers and directors of the Company.

On June 17, 2022, the Company entered into a master service agreement (the "MSA") with Telescope Innovations Corp. ("Telescope"), a related party of the Company. Dr. Andy Robinson, President and Chief Operating Officer of the Company and Robert Mintak, former Chief Executive Officer of the Company, are both independent directors of Telescope. Under the MSA, Telescope provides various research and development services for the purpose of developing new technologies. The Company incurred minimal costs related to the MSA during the nine months ended September 30, 2025. There were no costs incurred by the Company during the three months ended September 30, 2025. The Company incurred \$0.1 million and \$0.3 million, respectively, of costs related to the MSA during the three and nine months ended September 30, 2024.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

Related party receivables and payables are included in *Receivables – related parties* and *Accounts payable – related parties*, respectively, on the Company's condensed consolidated interim statements of financial position. The balances as of the periods indicated are as follows (in thousands):

	Septer	nber 30, 2025	Decen	nber 31, 2024
Receivables – related parties				
Joint Ventures ⁽¹⁾	\$	2,273	\$	1,274
Management and directors ⁽²⁾		739		_
Total	\$	3,012	\$	1,274
Accounts payable – related parties				
Joint Ventures ⁽³⁾	\$	4,700	\$	4,000
Management and directors ⁽²⁾		1,178		397
Total	\$	5,878	\$	4,397

- (1) Receivables related parties from the Joint Ventures represent receivables from SWA Lithium and Texas Lithium for reimbursement of costs paid by the Company on behalf of these entities.
- (2) Amounts due from or due to key management personnel are non-interest bearing, unsecured and have no fixed terms of repayment.
- (3) Accounts payable related parties to the Joint Ventures primarily represents cash received from SWA Lithium and Texas Lithium and is held by the Company in a separate account and designated for working capital needs and is currently due.

11. Financial Instruments and Financial Risk Management

Fair value is the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants. In arriving at a fair value measurement, the Company uses a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable. The three levels of inputs used to establish fair value are the following:

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly for similar items in active markets; and

Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company's policy is to recognize transfers into and out of fair value hierarchy levels at the end of the reporting period.

There were no transfers between Levels 1, 2 or 3 during the periods ended September 30, 2025 and December 31, 2024.

The following tables set forth the Company's financial assets measured at fair value by level within the fair value hierarchy for the periods indicated (in thousands):

September 30, 2025	Level	Level 1 Level		Level 3		Total	
Financial asset – FID ⁽¹⁾	\$	— \$	_	\$	51,895	\$	51,895
Investment in Aqualung		_	_		5,350		5,350

⁽¹⁾ Includes \$31.2 million and \$20.7 million related to SWA Lithium and Texas Lithium, respectively.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

December 31, 2024	 Level 1	Level 2	Level 3	Total
Financial asset – FID ⁽¹⁾	\$ _	\$ _	\$ 48,138	\$ 48,138
Investment in Aqualung	_	_	2,335	2,335

⁽¹⁾ Includes \$28.4 million and \$19.7 million related to SWA Lithium and Texas Lithium, respectively.

The Financial asset - FID is measured at fair value. The fair value of the financial asset was determined using a probability weighted discounted cash flow methodology which uses the S&P corporate bond yield curve based on the credit rating of the counterparty and considers the probability of the occurrence of reaching a positive FID in either of the Company's Joint Ventures. During the nine months ended September 30, 2025, the Company recorded a fair value gain on financial asset – FID of \$3.8 million. The increase in fair value is primarily attributable to the passage of time. During the nine months ended September 30, 2024, the Company recorded a fair value gain on financial asset – FID of \$1.9 million.

The Company's investment in Aqualung is measured at fair value on a recurring basis. Information relating to Aqualung is considered when determining its fair value. In addition to company-specific information, the Company takes into account trends in general market conditions and the share performance of comparable publicly-traded companies when valuing privately-held investments. As discussed in Note 6, during the nine months ended September 30, 2025, the Company recorded a fair value gain on Investment in Aqualung of \$2.8 million, primarily as a result of an equity investment transaction that was completed by Aqualung. There was no such gain recorded during the nine months ended September 30, 2024.

The Board has overall responsibility for the establishment and oversight of the Company's risk management framework. The Company's risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and in response to the Company's activities. Management regularly monitors compliance with the Company's risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.

The Company is exposed to various risks such as interest rate, credit, and liquidity risk. To manage these risks, management determines what activities must be undertaken to minimize potential exposure to risks. The objectives of the Company in managing risk are as follows:

- · maintaining sound financial condition;
- financing operations; and
- ensuring liquidity to all operations.

To satisfy these objectives, the Company monitors and manages these financial exposures as an integral part of its overall risk management program.

(i) Credit risk

Credit risk is the risk of loss if counterparties do not fulfill their contractual obligations and arises principally from cash deposits. The maximum credit risk is the total of the Company's financial assets, including cash and financial asset – FID. The Company maintains substantially all of its cash with two financial institutions. The majority of cash held with these institutions exceeds the amount of insurance provided on such deposits.

(ii) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company manages this risk by careful management of its working capital (current assets less current liabilities) to try to ensure its expenditures will not exceed available resources. As of September 30, 2025 and December 31, 2024, the Company had working capital of \$29.0 million and \$27.5 million, respectively.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(iii) Foreign exchange risk

Foreign exchange risk is the risk that the Company's financial instruments will fluctuate in value as a result of movement in foreign exchange rates. The Company does not use derivative instruments to reduce its exposure to foreign currency risk. The Company is exposed to currency risk through the following assets and liabilities denominated in USD (in thousands):

	Septer	December 31, 2024		
Cash	\$	21,769	\$	8,057
Investment in Aqualung		5,350		2,335
Accounts receivable		900		_
Accounts payable		92		47

At September 30, 2025, US dollar amounts were converted at a rate of USD 1.00 to CAD 1.39153. A 10% increase or decrease in the Canadian dollar relative to the US dollar would result in a change of approximately \$2.1 million in the Company's comprehensive loss for the year to date. At December 31, 2024, US dollar amounts were converted at a rate of USD 1.00 to CAD 1.43763. A 10% increase or decrease in the Canadian dollar relative to the US dollar would result in a change of approximately and \$0.8 million in the Company's comprehensive loss for the year to date.

12. Capital Management

The Company had \$32.1 million in cash on hand as of September 30, 2025.

On May 7, 2024, the Company entered into strategic partnerships with Equinor, in which the Company received an initial cash payment of \$30.0 million and a commitment by Equinor to invest up to an additional gross \$130.0 million in exchange for a 45% interest in SWA Lithium and Texas Lithium ("Smackover Lithium"), respectively. Included in Equinor's commitment to provide up to \$130.0 million in consideration are sole funding commitments of \$60.0 million post entrance into Smackover Lithium. These sole funding contributions by Equinor were fulfilled in the second quarter of 2025.

The Company's objectives when managing capital are to safeguard the Company's ability to pursue the exploration and development of its projects and to maintain a flexible capital structure. The Company's current capital structure is made up of common equity, with no long term debt or revolving credit facility obligations.

As the Company is currently in the exploration and development phase, none of its financial instruments are exposed to commodity price risk; however, the Company's ability to obtain long-term financing and its economic viability may be affected by commodity price volatility.

The Company may adjust how it manages its capital structure in light of changes in economic conditions and the risk characteristics of the underlying assets.

In order to carry out planned exploration and development of its projects and pay for administrative costs, the Company plans to spend its existing cash balance and may utilize other forms of financing.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company and its stage of development, is reasonable.

13. Contingencies

On January 27, 2022, a putative securities class action lawsuit was filed against the Company and certain former executives in the United States District Court for the Eastern District of New York, captioned Gloster v. Standard Lithium Ltd., et al., 22-cv-0507 (E.D.N.Y.) (the "Action"). The complaint purports to seek relief on behalf of a class of investors who purchased or otherwise acquired the Company's publicly traded securities between May 19, 2020 and November 17, 2021, and asserts violations of Section 10(b) of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") against all defendants and Section 20(a) of the Exchange Act against the individually-named defendants. On April

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

27, 2022, the court granted Curtis T. Arata's motion for appointment as lead plaintiff in the Action. Lead plaintiff filed an amended complaint on June 29, 2022, adding Andrew Robinson as a defendant and extending the class period to February 3, 2022. The amended complaint alleges, among other things, that during the proposed class period, defendants misrepresented and/or failed to disclose certain facts regarding the Company's LiSTR DLE technology and "final product lithium recovery percentage" at its DLE Demonstration Plant in southern Arkansas. The amended complaint seeks various forms of relief, including monetary damages in an unspecified amount. Defendants filed a motion to dismiss the amended complaint on August 10, 2022, which became fully briefed on September 28, 2022. On September 28, 2025, the court dismissed the amended complaint in full. On October 29, 2025, the plaintiff filed a notice of appeal.

14. Subsequent Events

Subsequent to September 30, 2025, the Company undertook the following significant events:

Public Offering

On October 20, 2025, the Company closed an underwritten public offering of 29,885,057 common shares at a price \$4.35 per share for gross proceeds of approximately \$130.0 million, and net proceeds of approximately \$122.2 million, post commission. The Company granted the underwriters an option to purchase up to an additional 4,482,758 common shares at the same price, exercisable for 30 days following October 16, 2025.

ATM Share Issuances

The Company issued 747,500 common shares at an average price of \$4.28 per share under the current ATM program, providing gross and net proceeds of \$3.2 million and \$3.1 million, respectively.